We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Incyte and Merck Announce the External Data Monitoring Committee (eDMC) to Review Key Phase 3 ECHO-301/KEYNOTE-252 Study Results for the Evaluation of Incyte's epacadostat in Combination with Merck's KEYTRUDA for Unresectable or Metastatic Melanoma Patien